News|Articles|December 30, 2024

Our Top 5 Social Media Posts of 2024

Author(s)Miranda Schmalfuhs

Check out our top five most engaged social media posts from the year 2024.

1.

2.

3.

4.

5.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: FDA Approves Ennumo

ByNicholas Jacobus

July 9th 2026

FDA Approves Ennumo to Decrease Incidence of Infection by Febrile Neutropenia

ByNicholas Jacobus

July 9th 2026

Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement

ByNicholas Jacobus

July 9th 2026

Pharmaceutical Executive Daily: AI as Reinvention

ByMike Hollan

July 8th 2026

Evogene Announces AI-Powered Small Molecule Discovery Focused Partnership with Blavatnik Center for Drug Discovery at Tel Aviv University

ByMike Hollan

July 8th 2026

Our Top 5 Social Media Posts of 2024

1.

2.

3.

4.

5.

Related Content

Pharmaceutical Executive Daily: FDA Approves Ennumo

FDA Approves Ennumo to Decrease Incidence of Infection by Febrile Neutropenia

Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement

Pharmaceutical Executive Daily: AI as Reinvention

Evogene Announces AI-Powered Small Molecule Discovery Focused Partnership with Blavatnik Center for Drug Discovery at Tel Aviv University

Trending on PharmExec

Novartis to Layoff 322 NJ Employees: Report

Launch is Just the Beginning: Rare Disease Care Requires Durability

Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement

“AI as Reinvention”: Transforming the Business of Medicine

FDA Approves Ennumo to Decrease Incidence of Infection by Febrile Neutropenia